Albion Financial Group Exact Sciences Corp Transaction History

Albion Financial Group

$1.29 Billion
Q1 2024

A detailed history of Albion Financial Group transactions in Exact Sciences Corp stock. As of the latest transaction made, Albion Financial Group holds 185 shares of EXAS stock, worth $7,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185

Previous 185 -0.0%

Holding current value

$7,990

Previous $13,000 7.69%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 01, 2023	SELL	$65.94 - $99.04 $32,970 - $49,520	-500 Reduced 72.99%	185 $12,000
Q1 2023 Apr 18, 2023	SELL	$47.19 - $70.77 $1,887 - $2,830	-40 Reduced 5.52%	685 $46,000
Q4 2022 Feb 03, 2023	BUY	$30.35 - $53.15 $1,214 - $2,126	40 Added 5.84%	725 $35,000
Q2 2022 Jul 29, 2022	BUY	$35.61 - $76.23 $6,587 - $14,102	185 Added 37.0%	685 $27,000
Q1 2022 May 09, 2022	SELL	$57.56 - $82.54 $230 - $330	-4 Reduced 0.79%	500 $35,000

Q4 2021 Feb 15, 2022	SELL	$72.5 - $100.68 $942 - $1,308	-13 Reduced 2.51%	504 $39,000
Q4 2020 Feb 19, 2021	BUY	$99.61 - $142.12 $51,498 - $73,476	517 New	517 $68,000
Q3 2018 Nov 20, 2018	SELL	$48.29 - $80.6 $618,884 - $1.03 Million	-12,816 Closed	0 $0
Q2 2018 Aug 15, 2018	SELL	$37.84 - $69.96 $16,838 - $31,132	-445 Reduced 3.36%	12,816 $766,000
Q1 2018 Apr 17, 2018	BUY	$39.82 - $57.53 $528,053 - $762,905	13,261 New	13,261 $535,000
Q4 2017 Feb 22, 2018	SELL	$46.49 - $60.51 $276,754 - $360,216	-5,953 Closed	0 $0
Q2 2017 Aug 15, 2017	BUY	N/A	5,953	5,953 $211,000

Others Institutions Holding EXAS

# of Institutions

699

Shares Held

160M

Call Options Held

5.84M

Put Options Held

2.58M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $7.64B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Albion Financial Group , based on Form 13F filings with the SEC.

News

Stay updated on Albion Financial Group with notifications on news.

Account

Albion Financial Group Exact Sciences Corp Transaction History